Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Zollinger-Ellison Syndrome 1Somatostatinoma 1Paraganglioma 1Neuroendocrine Tumors 1Insulinoma 1Glucagonoma 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1

Interventions

vandetanib 5selpercatinib 4Everolimus 4cabozantinib 3Sorafenib 3lenvatinib 2Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Gefitinib 2Capecitabine 2veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sargramostim 1sacubitril and valsartan sodium hydrate drug combination 1pralsetinib 1pentetreotide 1pazopanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lutetium Lu 177 dotatate 1cixutumumab 1aldesleukin 1Vorinostat 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Medullary × Acetates × Endocrine × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡